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Abstract
Background: Conventional whole brain radiotherapy (WBRT) has been established as the treatment standard in
patients with cerebral metastases from small-cell lung cancer (SCLC), however, it has only modest efficacy and
limited prospective data is available for WBRT as well as local treatments such as stereotactic radiosurgery (SRS).
Methods/design: The present single-center prospective randomized study, conducted at Heidelberg University
Hospital, compares neurocognitive function, as objectively measured by significant deterioration in Hopkins Verbal
Learning Test – Revised total recall at 3 months. Fifty-six patients will be randomized to receive either SRS of all
brain metastases (up to ten lesions) or WBRT. Secondary endpoints include intracranial progression (local tumor
progression and number of new cerebral metastases), extracranial progression, overall survival, death due to brain
metastases, local (neurological) progression-free survival, progression-free survival, changes in other cognitive
performance measures, quality of life and toxicity.
Discussion: Recent evidence suggests that SRS might be a promising treatment option for SCLC patients with
brain metastases. The present trial is the first to prospectively investigate the treatment response, toxicity and
neurocognition of WBRT and SRS in SCLC patients.
Trial registration: Clinicaltrials.gov NCT03297788. Registered September 29, 2017.
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Background
Patients suffering from small cell lung cancer (SCLC)
are at high risk for developing brain metastases (BM)
during the course of their disease. Between 40% and
50% of patients develop BM until time of death [1]
and the risk of developing BM further increases with
prolonged survival [2]. Prophylactic cranial irradiation
(PCI) is offered to limited disease patients if they re-
spond to first line regime [3–5]. However, up to 10–
15% of patients present with BM at initial diagnosis
[6–8], and if magnetic resonance imaging (MRI) is
used as a diagnostic tool for initial staging, the pro-
portion increases to 15–20% [9]. Treatment options
are usually limited to whole brain radiotherapy
(WBRT) and palliative chemotherapy [10]. The actual
effect of therapeutic WBRT has mainly been studied
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in small retrospective and non-randomized studies [2,
11–15]. Moreover, patients within recursive partition-
ing analysis (RPA) class III were commonly excluded
from any prospective BM trials that involved WBRT
[16, 17]. In a recent Japanese trial, prophylactic cra-
nial irradiation did not result in longer overall sur-
vival compared with observation plus regular MRI
follow-ups in patients with extensive disease (ED)
SCLC [18]. PCI is therefore no longer recommended
for patients with ED SCLC [19] when patients
undergo regular MRI brain scans during follow-up
[18]. Therefore, the number of patients with oligome-
tastasic cerebral disease might rise.
The present trial aims to investigate the treatment re-
sponse to ‘conventional whole brain radiotherapy’ and
‘stereotactic radiotherapy’ (SRS) in SCLC patients. The
primarily investigated endpoint is neurocognitive func-
tion, as objectively measured by significant deterior-
ation in Hopkins Verbal Learning Test – Revised
(HVLT-R) total recall at 3 months [20]. Secondary end-
points include intracranial progression (local tumor
progression, number of new cerebral metastases), extra-
cranial progression, overall survival, death due to brain
metastases, local (neurological) progression-free sur-
vival, progression-free survival, changes in other cogni-
tive performance measures, quality of life, and toxicity.
Methods/design
The study is a randomized phase II study with two study
arms. The standard arm is WBRT and the experimental
arm is SRS (Fig. 1). We hypothesized that patients
treated with WBRT would have inferior neurocognitive
function based on the HVLT-R [20] compared with pa-
tients treated with SRS alone.
Recruitment and randomization
Eligible patients who present at the Departments of
Radiation Oncology, University Hospital Heidelberg,
Germany, will be recruited to the study. Eligibility re-
quirements are:
Inclusion criteria
 Histologically confirmed ED SCLC
 MRI-confirmed cerebral metastasis (not resected,
maximum number of 10)
 Age ≥ 18 years of age
 For women with childbearing potential (and men),
adequate contraception
 Ability of subject to understand character and
individual consequences of the clinical trial
 Written informed consent (must be available before
enrolment in the trial)
Exclusion criteria
 Refusal of the patients to take part in the study
 Previous radiotherapy of the brain
 Patients who have not yet recovered from acute
high-grade toxicities of prior therapies
 Known carcinoma < 5 years ago (excluding
carcinoma in situ of the cervix, basal cell carcinoma,
squamous cell carcinoma of the skin) requiring
immediate treatment interfering with study therapy
 Pregnant or lactating women
 Participation in another clinical study or observation
period of competing trials, respectively
 MRI contraindication (i.e., cardiac pacemaker,
implanted defibrillator, certain cardiac valve
replacements, certain metal implants)
Fig. 1 Intervention and assessment schedule for the ENCEPHALON trial
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 Karnofsky Performance Score < 60
 Simultaneous cytotoxic chemotherapy
 Last application of chemotherapy/immunotherapy/
targeted therapy < 1 week before cerebral radiotherapy
After meeting eligibility criteria, 56 patients will be
randomly assigned to SRS or WBRT. To achieve com-
parable intervention groups, patients will be allocated in
a concealed fashion in a 1:1 ratio by means of
randomization using a centralized web-based tool
(www.randomizer.at). Randomization will be stratified
with respect to time of appearance (synchronous vs.
metachronous). Block randomization with varying block
lengths will be performed to achieve equal group sizes in
total. BM are defined as synchronous if discovered at the
time of initial diagnosis of the primary tumor or within
3 months thereafter. All other patients will be classified
as metachronous.
Assessment of the primary and secondary endpoints
The primary endpoint is neurocognition after cerebral
irradiation in SCLC patients treated with WBRT or SRS,
defined as a drop of at least 5 points from baseline in
HVLT-R total recall at 3 months. Secondary objectives
are intracranial progression (local tumor progression,
number of new cerebral metastases), extracranial pro-
gression, overall survival, death due to brain metastases,
local progression-free survival, progression-free survival,
changes in other cognitive performance measures, qual-
ity of life, and toxicity.
Time to progression is defined as the number of days
from randomization to the first occurrence of the re-
spective event. Overall survival time is defined as num-
ber of days from randomization until death or end of
follow-up. For patients alive at the end of the study, the
overall survival time will be censored at the time of the
last visit or follow-up contact.
Time to death due to BM is defined as number of days
from randomization until death due to BM or end of
follow-up, where death due to BM is defined as death
with intracranial progression as a component of cause of
death. Locally progression-free survival time is defined
as number of days from randomization until local tumor
progression, death without prior local progression, or
end of follow-up. The occurring events of interest will
be classified as (1) progression of cerebral metastases
present at baseline only, (2) occurrence of new cerebral
metastases only, (3) simultaneous detection of progres-
sion of cerebral metastases present at baseline and of
new metastases, and (4) death without local progression.
Time to extracranial progression is defined as number of
days from randomization until extracranial progression or
end of follow-up, where extracranial progression is the first
date on which progressive disease outside the brain
occurred according to the physician treating the primary
disease. Progression-free survival time is defined as number
of days from randomization until the first occurrence of
intracranial or extracranial progression, death without prior
progression, or end of follow-up. Intracranial progression is
defined as occurrence of progressive disease concerning
the pre-existing BM or the occurrence of new BM.
Local tumor progression (progressive disease, PD) is
defined as occurrence of intracranial progression) in the
area of the SRS.
Progression in the WBRT area is defined as occurrence
of intracranial tumor progression (progression of exist-
ing lesions and/or occurrence of new lesions).
The European Organization for Research and Treat-
ment of Cancer (EORTC) Questionnaire including brain
module (BN20) and the EORTC Paired Associated
Learning Questionnaire will be used. This study will use
the International Common Terminology Criteria for Ad-
verse Events (CTCAE) version 4.0 for toxicity and ad-
verse event reporting.
Patients are followed within the trial protocol for
12 months after baseline visit (T0). After T0, patients are
scheduled for follow-up visits every 3 months or as
needed clinically, including contrast-enhanced MRI as
well as thorough clinical-neurological assessment. Formal
neurocognitive testing and quality of life instrument test-
ing will be performed at baseline and during follow-up
visits every 3 months. The computer-administered
Cambridge Neuropsychological Test Automated Battery
(CANTAB) will be used to examine specific components
of cognition. The participants will be instructed to re-
spond to stimuli presented on a computer screen by
pressing a touch screen. Three tests were chosen to evalu-
ate further neurocognitive changes: Paired Associated
Learning for paired Associates Learning assesses visual
memory and new learning [21]; Reaction Time to provide
assessments of motor and mental response speeds [22], as
well as measures of movement time, reaction time, re-
sponse accuracy and impulsivity. Further, Spatial Working
Memory will be used [22], which requires retention and
manipulation of visuospatial information. Staff members
administering the tests were trained and approved by the
clinical neuropsychologist in the project group.
For the last patient in, the final study visit will be
12 months after baseline. This is considered the final
study visit (last patient out). All other patients will be
followed regularly as described in detail until death or
until 12 months after baseline. Beyond that, all patients
can be followed within routine clinical visits according
to national guidelines and survival and progression data
will be documented until ‘last patient out’. If death oc-
curs at less than 12 months or patients leave the study
prior to 12 months, they will be still included into the
intention-to-treat population.
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Radiotherapy
Treatment planning for WBRT
For WBRT, patients will be immobilized using an in-
dividually manufactured head mask. For treatment
planning, computed tomography (CT) without
contrast, contrast-enhanced CT as well as MRI will
be performed for optimal target definition. The target
volume includes the whole brain. WBRT will be
delivered by opposed lateral 6 MeV photon beams.
Dose constraints of normal tissue will be respected
according to QUANTEC reports [23, 24]. WBRT will
be applied in 10 once-daily fractions each of 3 Gy, to
a total dose of 30 Gy in 10 fractions to the whole
brain.
Treatment planning for SRS
MRI and CT imaging are 3-dimensionally fused using a
validated non-elastic imaging fusion algorithm and the
fusion results are cross-checked by an experienced phys-
ician and adapted if necessary.
Organs at risk are contoured and adapted on the
basis of CT scans and MRI. For target delineation, a
gross target volume (GTV) and a planning target
volume (PTV) are contoured. The basis for GTV
definition is the contrast-based, T1-weighted,
three-dimensional MPRAGE sequence. The GTV con-
sists of all contrast-enhanced tissue associated with
the target lesion and all additional tissue judged by
an experienced physician to be part of the suspect
target lesion (e.g. non-contrast-enhanced necrotic tis-
sue within or adjoining cystic metastatic lesions). To
the GTV, a PTV margin of 1 mm is added by iso-
tropic expansion that can be slightly modified if
deemed necessary by the treating physician (e.g.,
intersection with adjoining organs at risk).
Treatment planning for SRS will be performed using
Accuray’s Multiplan or subsequent approved treatment
planning systems for CyberKnife®.
SRS will be applied in one to a maximum of six frac-
tions. For SRS, the dose prescription to the PTV will be
as follows (risk adapted SRS dose prescription volume
and location based):
– 20 Gy to the 70%-isodose (lesions < 2 cm max.
diameter)
– 18 Gy to the 70%-isodose (lesions 2–3 cm max.
diameter)
– 6 × 5 Gy to the conformally surrounding isodose
(lesions > 3 cm max. diameter or brain stem)
Dose constraints of normal tissue will be respected ac-
cording to QUANTEC reports [23, 24] and extensive
clinical experience at our institution.
Statistical analysis
The primary hypothesis of the trial is that there is a differ-
ence between the two treatment arms with respect to the
primary endpoint, defined as a drop of at least 5 points
from baseline in HVLT-R total recall at 3 months after
baseline (T0). Chang et al. [25] observed deterioration
probabilities of 0.64 for SRS +WBRT and 0.20 for SRS
alone at 4 months after baseline. Based on those results,
assuming a deterioration probability of 0.20 for the SRS
arm and 0.64 for the WBRT arm in our trial, n = 19 pa-
tients per arm are required to demonstrate a difference be-
tween treatment arms applying a χ2 test at a two-sided
significance level of α = 0.05 with a probability of 1–β = 0.8.
Assuming exponentially distributed survival times with a
median of 6 months for both groups, 29.3% of all random-
ized patients are expected to have died before the measure-
ment of the primary endpoint. Thus, n = 28 patients per
group are required to yield a sufficiently high power for a
comparison of the deterioration rate within the two
groups. Statistical analysis is based on the International
Conference on Harmonization Guidelines Structure and
Content of Clinical Study Reports and Statistical Principles
for Clinical Trials. A detailed methodology for the statis-
tical analysis will be described in the statistical analysis
plan, which will be finalized before database lock. Statis-
tical analysis will be performed using SAS v9.4 or higher.
Efficacy evaluation
The primary hypothesis of the trial is that there is a differ-
ence between the two treatment arms with respect to the
primary endpoint, defined as a drop of at least 5 points
from baseline in HVLT-R total recall at 3 months. With
πSRS being the deterioration probability in the SRS arm
and πWBRT being the deterioration probability in the
WBRT arm, the null hypothesis H0: πSRS = πWBRT is tested
against its alternative H1: πSRS ≠ πWBRT at a two-sided
significance level of α = 0.05 using a Cochran–Mantel–
Haenszel test adjusting for the confounder time of appear-
ance (synchronous vs. metachronous). Missing data for
the primary outcome variable will be replaced by using
multiple imputation which takes the covariates of treat-
ment group, time of appearance (synchronous vs. meta-
chronous), and the baseline HVLT-R total recall score into
account by application of the fully conditional specifica-
tion method [26]. For the secondary time-to-event end-
points overall survival, local progression-free survival, and
locoregional progression-free survival, median event times
and 1-year rates will be given with 95% confidence inter-
vals and Kaplan–Meier curves will be calculated for both
treatment groups. A (descriptive) log-rank test stratified
for time of appearance (synchronous vs. metachronous)
will be performed in order to assess differences between
the two treatment groups, and a descriptive P value will
be given. A Cox proportional hazard model with overall
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survival as dependent variables well as treatment group
and time of appearance as independent factors will be fit-
ted to estimate the hazard ratio for the treatment group
together with a 95% confidence interval.
All further secondary outcomes will be analyzed de-
scriptively, and descriptive P values will be reported to-
gether with corresponding 95% confidence intervals.
Ethical issues, information, and safety
The study protocol, Patient Information sheet, and Dec-
laration of Informed Consent was approved by the Hei-
delberg University Ethics Committee (S-470/2017). The
procedures described in the submitted study protocol re-
garding the performance, evaluation, and documentation
of this study has been selected in such a way that the
principles of the Good Clinical Practice (GCP) guidelines
are observed. The regulations regarding medical confi-
dentiality and data protection are fulfilled. Informed
consent will be obtained from all participants in the
study.
Concerning radiation protection law (StrSchV), the au-
thors of this protocol presume that a submission to the
Bundesamt für Strahlenschutz (BfS) is not required. To
confirm this position, the investigators submitted this
protocol to the expert commission of the German Soci-
ety of Radiation Oncology ENCEPHALON Clinical Trial
Protocol Version 1.0, Date 07/2017 (DEGRO No. 132)
(Additional file 1; SPIRIT Checklist).
Discussion
The primary aim of this trial is to exploratively investi-
gate the effect of SRS compared to WBRT in patients
with BM from SCLC. Currently, according to national
guidelines, the recommendation for patients with BM
from SCLC, regardless of the number of BM, is WBRT
[10]. The actual evidence behind those recommenda-
tions is low and mainly based on retrospective studies
from the last three decades and is analogically reasoned
by previous PCI studies [3–6, 27]. In a recent Japanese
trial, prophylactic cranial irradiation did not result in
longer overall survival compared with observation in pa-
tients with ED SCLC and PCI is therefore no longer rec-
ommended for patients with extensive disease SCLC
when patients receive regular MRI examinations during
follow-up. Furthermore, if SCLC patients are regularly
checked with MRI, the actual number of patients with
limited number of BM might rise. The general use of
WBRT in SCLC patients is additionally supported by the
general paradigm of a diffuse intracranial disease pat-
tern; even so, these beliefs derive from a pre-MRI era.
The EORTC conducted a prospective, phase II study be-
tween 1989 and 1995 that included patients (n = 22) with
brain-only metastases SCLC to evaluate the efficacy of
WBRT [28]. The median response duration in patients
with an objective response was 5.4 months, and the me-
dian survival of all patients was 4.7 months. A number
of retrospective studies investigated prognostic factors
and identified subgroups of SCLC patients with a favor-
able prognosis [15, 29–31]. In a recent report [5], we in-
vestigated 229 SCLC patients with BM from SCLC;
median overall survival after WBRT was 6 months. The
main prognostic factors associated with overall survival
were performance status, time of appearance of intracra-
nial disease (synchronous vs. metachronous), initial re-
sponse to chemotherapy, and higher RPA class.
Interestingly, patients in RPA class I showed a median
survival after WBRT of 17 months and had a compar-
able outcome to patients with non-cerebral disease
treated with PCI. Furthermore, 39% of patients had 1–5
BM and the majority of patients received staging with
cerebral MRI prior to treatment [32]. The recently de-
veloped disease-specific prognostic score for patients
with BM from SCLC was even more prognostic than
RPA score and diagnosis-specific graded prognostic as-
sessment score [29] and revealed a subgroup of patients
with a very short survival (class I) and a subgroup with a
favorable prognosis (class II) [33]. The disease-specific
prognostic score for patients with BM from SCLC will be
validated within the ENCEPHALON trial. Because of the
multiple prognostic factors and differences in outcomes in
patients with BM from SCLC, a one- fits-all treatment
framework, in which all patients are automatically recom-
mended for WBRT, is no longer appropriate and the ac-
tual evidence for this recommendation is missing.
Radiosurgery and surgery are possible treatment options
in patients with a limited number of BM and for patients
with BM of less than 3 cm in diameter from solid tumors,
except SCLC patients. For patients with 2–4 metastases
and with a life expectancy of more than 3 months, radio-
surgery should be used rather than WBRT [34–38]. A re-
cent Japanese trial investigated the effect of SRS in 1194
patients with multiple brain metastases from solid tumors.
The authors concluded that SRS in patients with 5–10
BM is non-inferior to that in patients with 2–4 BM.
Considering the minimal invasiveness of stereotactic
radiosurgery and the fewer side effects than with WBRT,
SRS might be a suitable alternative for patients with up to
10 brain metastases [39].
For SCLC patients there is only limited prospective
data available regarding locally ablative treatments or
SRS. However, a number of retrospective studies investi-
gated the effect of SRS as a treatment in a primary set-
ting and as a salvage option after prior WBRT or PCI in
SCLC patients [32, 40–44]. Patients who received SRS
instead of WBRT showed a comparable or even better
survival compared to patients with WBRT. This is, of
course, biased by the retrospective design and the lim-
ited number of BM in the patient group that received
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SRS. On the other hand, this implies that a subgroup of
patients might be suitable for SRS. In a prospective co-
hort trial, Li et al. [45] evaluated SRS versus SRS +
WBRT and WBRT alone in patients with a single BM of
SCLC or non-SCLC. The study did not reveal a statisti-
cally significant difference concerning median survival
(9.3 vs. 10.6 months) or recurrence and progression. The
authors concluded that SRS-alone and SRS +WBRT
seem superior to WBRT-alone in prolonging overall sur-
vival, local control, and improving quality of life in pa-
tients with single BM from lung carcinoma.
Chang et al. [25] prospectively evaluated neurocognitive
outcome in 58 patients with 1–3 BM from solid tumors
and were randomly assigned to SRS +WBRT or SRS
alone. The primary endpoint was neurocognitive function
measured as a significant deterioration (5-point drop com-
pared with baseline) in HVLT-R total recall at 4 months.
After 58 patients were recruited, the trial was stopped on
the basis that there was a high probability (96%) that pa-
tients receiving SRS plus WBRT were significantly more
likely to show a decline in learning and memory function
at 4 months than patients assigned to receive SRS alone.
SCLC patients often die from thoracic progression, rather
than of progression of BM. Therefore, especially for a pa-
tient group with a favorable prognosis, the preservation of
cognitive function and quality of life is essential.
Trial status
Recruiting.
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